Antibodies that specifically bind to tr2
CA 2482938 A1 · Owner: Human Genome Sciences, Inc. · Inventors: Rosen, Craig A.; Ruben, Steven M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to antibodies and related molecules that specifically bind to TR2 proteins. Such antibodies have uses for example, in , the prevention and treatment of cancers and other proliferative disorders autoimmune disorders, immunodeficiencies and/or HSV infection. The invention also relates to nucleic acid molecules encoding anti-TR2 antibodies vectors , and host cells containing these nucleic acids and methods for producing the , same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders comprising , administering to …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 10, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 10, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 10, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.